InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $8.290 0.08 (0.96%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$418 Notification of cessation of securities - CUV 2 Oct 2024 8:50AM $14.520 $8.290 fallen by 42.91%
$418 Canadian New Drug Submission for SCENESSE in EPP filed 1 Oct 2024 8:23AM $14.020 $8.290 fallen by 40.87%
$418 Update - Notification of buy-back - CUV 27 Sep 2024 8:30AM $14.300 $8.290 fallen by 42.03%
$418 Update - Notification of buy-back - CUV 26 Sep 2024 8:28AM $14.320 $8.290 fallen by 42.11%
$418 SCENESSE data to be presented at global porphyria conference 20 Sep 2024 8:22AM $14.800 $8.290 fallen by 43.99%
$418 Update - Notification of buy-back - CUV 19 Sep 2024 8:37AM $14.980 $8.290 fallen by 44.66%
$418 Notice of Annual General Meeting/Proxy Form 13 Sep 2024 9:24AM $15.120 $8.290 fallen by 45.17%
$418 Change of AGM Time of Meeting 13 Sep 2024 9:24AM $15.120 $8.290 fallen by 45.17%
$418 Initial Director's Interest Notice - Pearl Grimes 10 Sep 2024 3:22PM $14.580 $8.290 fallen by 43.14%
$418 Initial Director's Interest Notice - Guy van Dievoet 10 Sep 2024 3:22PM $14.580 $8.290 fallen by 43.14%
$418 Initial Director's Interest Notice - Matthew Pringle 10 Sep 2024 3:21PM $14.580 $8.290 fallen by 43.14%
$418 Update - Notification of buy-back - CUV 10 Sep 2024 8:20AM $14.550 $8.290 fallen by 43.02%
$418 Chair's letter to Shareholders 9 Sep 2024 9:26AM $14.720 $8.290 fallen by 43.68%
$418 CLINUVEL Board Renewal, Expansion 6 Sep 2024 9:06AM $14.820 $8.290 fallen by 44.06%
$418 Update - Notification of buy-back - CUV 6 Sep 2024 8:22AM $14.820 $8.290 fallen by 44.06%
$418 Update - Notification of buy-back - CUV 5 Sep 2024 8:53AM $15.190 $8.290 fallen by 45.42%
$418 Update - Notification of buy-back - CUV 4 Sep 2024 8:23AM $15.420 $8.290 fallen by 46.24%
$418 CLINUVEL Investor Webinar 30 Aug 2024 9:48AM $15.880 $8.290 fallen by 47.80%
$418 Corporate Governance Statement 29 Aug 2024 9:33AM $13.900 $8.290 fallen by 40.36%
$418 Appendix 4G 29 Aug 2024 9:32AM $13.900 $8.290 fallen by 40.36%
$418 Investor Presentation 29 Aug 2024 9:32AM $13.900 $8.290 fallen by 40.36%
$418 CLINUVEL delivers increases in annual revenue, profit 29 Aug 2024 9:32AM $13.900 $8.290 fallen by 40.36%
$418 Dividend/Distribution - CUV 29 Aug 2024 9:30AM $13.900 $8.290 fallen by 40.36%
$418 Appendix 4E and Annual Report to Shareholders 2024 29 Aug 2024 9:22AM $13.900 $8.290 fallen by 40.36%
$418 Ceasing to be a substantial holder 23 Aug 2024 6:36PM $13.370 $8.290 fallen by 38%

126 - 150 of 872 results

Page 6 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.